V

Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645

Watchlist Manager
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
Watchlist
Price: 26.67 CNY -2.2% Market Closed
Market Cap: 12.5B CNY
Section:
 

Relative Value

The Relative Value of one Vcanbio Cell & Gene Engineering Corp Ltd stock under the Base Case scenario is 15.44 CNY. Compared to the current market price of 26.67 CNY, Vcanbio Cell & Gene Engineering Corp Ltd is Overvalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
15.44 CNY
Overvaluation 42%
Relative Value
Price
V
Worst Case
Base Case
Best Case

Valuation Multiples

8.5
P/S
P/S
Price to Sales
8.5
vs History
3
vs Industry
53
Median 3Y
5.6
Median 5Y
6.1
Industry
8.1
Forward
6.9
More Details
167
P/E
P/E
Price to Earnings
167
vs History
1
vs Industry
2
Median 3Y
76.1
Median 5Y
74.5
Industry
23.7
Forward
77.7
More Details
37.7
P/OCF
P/OCF
Price to OCF
37.7
vs History
7
vs Industry
5
Median 3Y
32.4
Median 5Y
32.5
Industry
22.6
More Details
44.7
P/FCFE
P/FCFE
Price to FCFE
44.7
vs History
69
vs Industry
4
Median 3Y
45.8
Median 5Y
49.4
Industry
25.7
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
1
vs Industry
32
Median 3Y
2.5
Median 5Y
2.6
Industry
3.3
More Details
8.5
EV/S
EV/S
Enterprise Value to Sales
8.5
vs History
1
vs Industry
48
Median 3Y
4.7
Median 5Y
5
Industry
8.4
Forward
7
More Details
12.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
12.7
vs History
1
vs Industry
45
Median 3Y
6.9
Median 5Y
7.4
Industry
10.4
More Details
102.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
102.6
vs History
3
vs Industry
2
Median 3Y
48
Median 5Y
50.6
Industry
5.9
Forward
39.7
More Details
102.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
102.6
vs History
3
vs Industry
2
Median 3Y
48
Median 5Y
50.6
Industry
6.4
More Details
37.9
EV/OCF
EV/OCF
Enterprise Value to OCF
37.9
vs History
4
vs Industry
5
Median 3Y
26.8
Median 5Y
27.8
Industry
8.2
More Details
44.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
44.9
vs History
22
vs Industry
3
Median 3Y
38.5
Median 5Y
40.8
Industry
6.4
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
20
vs Industry
43
Median 3Y
2.1
Median 5Y
2.1
Industry
5.8
More Details

Multiples Across Competitors

Competitors Multiples
Vcanbio Cell & Gene Engineering Corp Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
12.5B CNY 8.5 167 102.6 102.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 178 916.3 -162 447.3 -197 262.9 -195 011.9
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.2 -526 -572.7 -557.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
P/E Multiple
Earnings Growth PEG
CN
V
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
Average P/E: 173.1
167
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 447.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
V
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
Average EV/EBITDA: 44.7
102.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 262.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
V
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
Average EV/EBIT: 49.7
102.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 011.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.